FYERS
Home
/
Stocks
/
Profit Loss
/
Medicamen Biotech Profit & Loss

Medicamen Biotech Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021Dec 2020Sep 2020Jun 2020Mar 2020Dec 2019Sep 2019Jun 2019Mar 2019
₹48 Cr₹61 Cr₹47 Cr₹47 Cr₹43 Cr₹30 Cr₹45 Cr₹45 Cr₹43 Cr₹47 Cr₹47 Cr₹44 Cr₹42 Cr₹39 Cr₹36 Cr₹34 Cr₹33 Cr₹23 Cr₹33 Cr₹33 Cr₹28 Cr₹21 Cr₹33 Cr₹31 Cr₹28 Cr₹24 Cr₹35 Cr₹36 Cr₹31 Cr₹24 Cr
₹86 L₹2 Cr₹54 L₹37 L₹47 L₹5 Cr₹14 L₹29 L₹59 L₹57 L₹83 L₹55 L₹38 L₹35 L₹63 L₹53 L₹96 L₹34 L₹83 L₹48 L₹8 L₹54 L₹10,000₹13 L₹8 L₹1 Cr₹45 L₹35 L₹4 L₹7 L
₹49 Cr₹62 Cr₹47 Cr₹48 Cr₹44 Cr₹35 Cr₹45 Cr₹45 Cr₹44 Cr₹48 Cr₹47 Cr₹44 Cr₹42 Cr₹39 Cr₹36 Cr₹34 Cr₹34 Cr₹23 Cr₹33 Cr₹33 Cr₹28 Cr₹22 Cr₹33 Cr₹31 Cr₹28 Cr₹25 Cr₹36 Cr₹36 Cr₹31 Cr₹24 Cr
₹45 Cr₹57 Cr₹44 Cr₹44 Cr₹40 Cr₹32 Cr₹41 Cr₹42 Cr₹41 Cr₹43 Cr₹43 Cr₹41 Cr₹37 Cr₹34 Cr₹31 Cr₹29 Cr₹29 Cr₹19 Cr₹28 Cr₹28 Cr₹23 Cr₹17 Cr₹28 Cr₹26 Cr₹24 Cr₹21 Cr₹31 Cr₹30 Cr₹27 Cr₹20 Cr
₹5 Cr₹7 Cr₹5 Cr₹6 Cr₹5 Cr₹4 Cr₹7 Cr₹6 Cr₹4 Cr₹6 Cr₹6 Cr₹5 Cr₹7 Cr₹7 Cr₹7 Cr₹6 Cr₹7 Cr₹5 Cr₹7 Cr₹7 Cr₹6 Cr₹5 Cr₹5 Cr₹6 Cr₹4 Cr₹4 Cr₹6 Cr₹6 Cr₹5 Cr₹4 Cr
₹83 L₹38 L₹97 L₹99 L₹1 Cr₹65 L₹76 L₹1 Cr₹71 L₹2 Cr₹65 L₹91 L₹96 L₹86 L₹68 L₹62 L₹77 L₹56 L₹49 L₹30 L₹4 L₹36 L₹9 L₹38 L₹24 L₹0₹19 L₹21 L₹16 L₹20 L
₹3 Cr₹5 Cr₹2 Cr₹3 Cr₹2 Cr₹2 Cr₹4 Cr₹2 Cr₹2 Cr₹3 Cr₹3 Cr₹2 Cr₹5 Cr₹4 Cr₹4 Cr₹4 Cr₹4 Cr₹3 Cr₹5 Cr₹5 Cr₹5 Cr₹4 Cr₹4 Cr₹5 Cr₹3 Cr₹3 Cr₹5 Cr₹5 Cr₹4 Cr₹4 Cr
₹2 Cr₹4 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹3 Cr₹91 L₹80 L₹2 Cr₹2 Cr₹1 Cr₹4 Cr₹4 Cr₹4 Cr₹4 Cr₹4 Cr₹3 Cr₹4 Cr₹4 Cr₹4 Cr₹4 Cr₹3 Cr₹3 Cr₹2 Cr₹2 Cr₹4 Cr₹4 Cr₹3 Cr₹2 Cr

Share Price Live Stats

Open (₹)258.95
Volume (₹)10,373.00
High (₹)267.80
Upper Circuit275.25
Low (₹)254.00
Lower Circuit249.05
Prev Close262.15
52W High (₹)447.65
Price267.80
52W Low (₹)212.40

Share Market Cap & Key Ratios Overview

M.Cap (₹)368.87 Cr
Div. Yield (%)0.38
PE Ratio34.06
Debt to Equity0.19
Price to Book1.18
Book Value190.02
EPS (TTM)7.70
Face Value10.00
ROE (%)4.23

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
LAURUSLABSNSE
ZYDUSLIFENSE
DRREDDYNSE
CIPLANSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
MEDICAMEQ-BENSE
LTP
1W Low
1W High
Market cap (₹)
1773.4-4.3 (-0.24%)
1722
1810.40
4,25,150Cr
10037.5+257.5 (2.63%)
9863
10067
2,66,265Cr
4738.5+125.1 (2.71%)
4553
4738.50
1,76,301Cr
2323.8-81.7 (-3.40%)
2252.40
2441.90
1,25,352Cr
1188.1-57.4 (-4.61%)
1182.40
1266.60
1,23,591Cr
1374+22 (1.63%)
1336.70
1376.70
1,14,351Cr
1402+23.1 (1.68%)
1364.60
1402
1,12,474Cr
2537.9+45.1 (1.81%)
2457.90
2540
1,02,315Cr
1705+23.6 (1.40%)
1656.20
1724.60
97,757Cr
2008.6-2.4 (-0.12%)
1988.90
2062.10
92,007Cr
267.8+11.6 (4.53%)
247.10
267.80
369Cr

Key Highlights of Medicamen Biotech Ltd’s P&L

In 2025-03-31, Medicamen Biotech Ltd reported total revenue of ₹168.8Cr, compared with ₹181.63Cr in 2024-03-31, reflecting Medicamen Biotech Ltd turnover.

Depreciation was ₹7.07Cr and finance costs were ₹3.72Cr in 2025-03-31

Profit Before Tax (PBT) has been ₹9.88Cr in 2025-03-31 as compared to ₹13.08Cr in 2024-03-31.

Net Profit (PAT) was ₹6.56Cr in 2025-03-31 compared with ₹9.49Cr in 2024-03-31.

Earnings per share (EPS) were ₹5.16 in 2025-03-31, compared with ₹7.47 in 2024-03-31.